Product Information
GLATIRAMER 40 MG/ML SYRINGE is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $86.0952 per ML under NDC 00378696112. Its NADAC has been published 363 times since Oct 23, 2019.
FDA first approved this application on Oct 3, 2017. Its Orange Book therapeutic-equivalence code is AP.
Strength
40 mg/mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378696112
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
GLATIRAMER ACETATEApproval Type
Generic (ANDA)
FDA Application
ANDA206936FDA Approved
10/3/2017
TE Code
AP
On Market Since
10/4/2017
Price Statistics
The NADAC for GLATIRAMER 40 MG/ML SYRINGE has been published 363 times since Oct 23, 2019, and over the history we have for it it has declined 45.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $86.0952 per ML |
|---|---|
| All-time high | $159.2183 (Nov 13, 2019) |
| All-time low | $86.0952 (Sep 23, 2026) |
| 52-week high | $106.9416 |
| 52-week low | $86.0952 |
| Median price | $125.4714 |
| Average price | $120.9315 |
| Largest weekly change | -14.8% (Nov 20, 2024) |
| Weeks tracked | 363 |
| Tracking since | Oct 23, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Glatiramer market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Glatiramer market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GLATIRAMER 40 MG/ML SYRINGE?
The current National Average Drug Acquisition Cost (NADAC) for GLATIRAMER 40 MG/ML SYRINGE, manufactured by Mylan Pharmaceuticals Inc., is $86.0952 per ML (NDC 00378696112), effective Sep 30, 2026.
How has the price of GLATIRAMER 40 MG/ML SYRINGE changed over time?
Over the history we have for it, the NADAC for GLATIRAMER 40 MG/ML SYRINGE has declined 45.9%. It has been tracked across 363 weekly CMS publications since Oct 23, 2019.
What are the highest and lowest recorded NADAC prices for GLATIRAMER 40 MG/ML SYRINGE?
Since Oct 23, 2019, the NADAC for GLATIRAMER 40 MG/ML SYRINGE has ranged from a low of $86.0952 (Sep 23, 2026) to a high of $159.2183 (Nov 13, 2019), with a median of $125.4714 per ML.
Are there cheaper alternatives to GLATIRAMER 40 MG/ML SYRINGE?
No other NADAC-published product currently shares the active ingredient and strength of GLATIRAMER 40 MG/ML SYRINGE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GLATIRAMER 40 MG/ML SYRINGE?
GLATIRAMER 40 MG/ML SYRINGE (NDC 00378696112) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.